Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 973 to 974 of 974 entries
Sorted by: Best Match Show Resources per page
Postoperative quality of life and therapy-related impairments of oral cancer in relation to time-distance since treatment.

Journal of cancer survivorship : research and practice

Jehn P, Spalthoff S, Lentge F, Zeller AN, Tavassol F, Neuhaus MT, Eckstein FM, Krüskemper G, Gellrich NC, Korn P.
PMID: 34609700
J Cancer Surviv. 2021 Oct 05; doi: 10.1007/s11764-021-01118-3. Epub 2021 Oct 05.

PURPOSE: Oral cancer resection can cause physical and psychological impairments that influence the quality of life (QoL). Depending on the postoperative time-distance, the occurrence and intensity of these impairments may change. We evaluated the sequelae and changes in therapy-related...

Cite
Jehn P, Spalthoff S, Lentge F, et al. Postoperative quality of life and therapy-related impairments of oral cancer in relation to time-distance since treatment. J Cancer Surviv. 2021;doi: 10.1007/s11764-021-01118-3.
Jehn, P., Spalthoff, S., Lentge, F., Zeller, A. N., Tavassol, F., Neuhaus, M. T., Eckstein, F. M., Krüskemper, G., Gellrich, N. C., & Korn, P. (2021). Postoperative quality of life and therapy-related impairments of oral cancer in relation to time-distance since treatment. Journal of cancer survivorship : research and practice, . https://doi.org/10.1007/s11764-021-01118-3
Jehn, Philipp, et al. "Postoperative quality of life and therapy-related impairments of oral cancer in relation to time-distance since treatment." Journal of cancer survivorship : research and practice vol. (2021). doi: https://doi.org/10.1007/s11764-021-01118-3
Jehn P, Spalthoff S, Lentge F, Zeller AN, Tavassol F, Neuhaus MT, Eckstein FM, Krüskemper G, Gellrich NC, Korn P. Postoperative quality of life and therapy-related impairments of oral cancer in relation to time-distance since treatment. J Cancer Surviv. 2021 Oct 05; doi: 10.1007/s11764-021-01118-3. Epub 2021 Oct 05. PMID: 34609700.
Copy Download .nbib Format: NLM
Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial.

JAMA oncology

Siva S, Bressel M, Mai T, Le H, Vinod S, de Silva H, Macdonald S, Skala M, Hardcastle N, Rezo A, Pryor D, Gill S, Higgs B, Wagenfuehr K, Montgomery R, Awad R, Chesson B, Eade T, Wong W, Sasso G, De Abreu Lourenco R, Kron T, Ball D, Neeson P.
PMID: 34455431
JAMA Oncol. 2021 Oct 01;7(10):1476-1485. doi: 10.1001/jamaoncol.2021.2939.

IMPORTANCE: Evidence is lacking from randomized clinical trials to guide the optimal approach for stereotactic ablative body radiotherapy (SABR) in patients with pulmonary oligometastases.OBJECTIVE: To assess whether single-fraction or multifraction SABR is more effective for the treatment of patients...

Cite
Siva S, Bressel M, Mai T, et al. Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021;7(10):1476-1485doi: 10.1001/jamaoncol.2021.2939.
Siva, S., Bressel, M., Mai, T., Le, H., Vinod, S., de Silva, H., Macdonald, S., Skala, M., Hardcastle, N., Rezo, A., Pryor, D., Gill, S., Higgs, B., Wagenfuehr, K., Montgomery, R., Awad, R., Chesson, B., Eade, T., Wong, W., Sasso, G., De Abreu Lourenco, R., Kron, T., Ball, D., Neeson, P. (2021). Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial. JAMA oncology, 7(10), 1476-1485. https://doi.org/10.1001/jamaoncol.2021.2939
Siva, Shankar, et al. "Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial." JAMA oncology vol. 7,10 (2021): 1476-1485. doi: https://doi.org/10.1001/jamaoncol.2021.2939
Siva S, Bressel M, Mai T, Le H, Vinod S, de Silva H, Macdonald S, Skala M, Hardcastle N, Rezo A, Pryor D, Gill S, Higgs B, Wagenfuehr K, Montgomery R, Awad R, Chesson B, Eade T, Wong W, Sasso G, De Abreu Lourenco R, Kron T, Ball D, Neeson P. Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021 Oct 01;7(10):1476-1485. doi: 10.1001/jamaoncol.2021.2939. PMID: 34455431; PMCID: PMC8404145.
Copy Download .nbib Format: NLM
Showing 973 to 974 of 974 entries